Early Switch in Moderate ARDS (SWITCH-ARDS)

November 13, 2026 updated by: DEMOSTHENES MAKRIS, University of Thessaly

Early Switch to Assisted Ventilation in Patients With Moderate ARDS: a Physiological Study

The optimal timing for transition from controlled to assisted mechanical ventilation in patients with acute respiratory distress syndrome (ARDS) remains uncertain. Excessive spontaneous respiratory effort may promote injurious transpulmonary pressure swings and heterogeneous regional ventilation, whereas unnecessary prolongation of controlled ventilation may increase sedation exposure and diaphragmatic dysfunction.

This prospective, single-center physiological interventional study will enroll mechanically ventilated adults with ARDS and a PaO₂/FiO₂ ratio >100 and ≤200 mmHg, measured during PEEP=5 cmH2O, who are receiving controlled mechanical ventilation. Participants will undergo a protocolized 30-minute transition from controlled to assisted mechanical ventilation after reduction of sedation sufficient to allow spontaneous respiratory activity.

Respiratory effort and drive, airway and esophageal pressures, respiratory flow, respiratory mechanics, gas exchange, and regional ventilation measured by electrical impedance tomography will be assessed before and during the transition. Participants will subsequently be followed for 48 hours to determine whether assisted ventilation can be maintained without return to fully controlled mechanical ventilation.

Study Overview

Detailed Description

Participants meeting eligibility criteria will initially remain on their clinically prescribed controlled mechanical ventilation. Sedation will be gradually reduced to permit the reappearance of spontaneous respiratory activity while avoiding clinically significant agitation or patient-ventilator dyssynchrony. Once spontaneous respiratory activity is present, participants will be transitioned to assisted mechanical ventilation. Positive end-expiratory pressure will be maintained at the pre-transition level, which will have been titrated with the use of esophageal manometry so as to achieve an end-expiratory trans-pulmonary pressure above 0 cmH2O, and inspired oxygen fraction will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain protective targets: esophageal pressure swings= 3-15 cmH2O (diaphragm protective) and transpulmonary pressure swings < 15-20 cmH2O (lung protective).

The physiological transition trial will last 30 minutes. Continuous recordings of airway pressure, esophageal pressure, respiratory flow, and electrical impedance tomography will be obtained. Respiratory drive will additionally be assessed using airway occlusion pressure at 100 milliseconds (P0.1).

Three prespecified analysis periods will be used: T0, the final 5 minutes during controlled ventilation before transition; T1, the first 5 minutes of assisted ventilation; and T2, minutes 25-30 of assisted ventilation.

Electrical impedance tomography analyses will include regional distribution of tidal ventilation, global inhomogeneity index, end-expiratory lung impedance, ventral-to-dorsal ventilation distribution, center of ventilation, and occurrence or magnitude of pendelluft. Respiratory mechanics analyses will include esophageal pressure swing, pressure-time product of the esophageal pressure, transpulmonary pressure, respiratory system elastance, chest-wall elastance, and lung elastance.

The transition trial will be stopped if prespecified clinical intolerance or safety criteria occur. Participants who do not tolerate the trial will be returned to controlled ventilation according to clinical requirements.

After completion of the 30-minute trial, participants will be followed for 48 hours. Successful transition will be defined as maintenance of assisted mechanical ventilation without the need to return to fully controlled mechanical ventilation during this period.

Study Type

Observational

Enrollment (Estimated)

30

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

      • Larissa, Greece
        • Recruiting
        • Critical Care Department, University Hospital of Larisa
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Patients with ARDS of severe to moderate severity (100<PaO2/FiO2<200 mmHg).

Description

Inclusion Criteria:

  • Age ≥18 years
  • Endotracheally intubated and receiving invasive mechanical ventilation
  • Meets diagnostic criteria for acute respiratory distress syndrome
  • PaO₂/FiO₂ ratio >100 and ≤200 mmHg
  • Receiving controlled mechanical ventilation immediately before the transition trial

Exclusion Criteria:

  • Implanted electrical cardiac or other device incompatible with electrical impedance tomography
  • Thoracic drains, extensive dressings, or other factors preventing appropriate EIT belt placement
  • Contraindication to placement of an esophageal balloon catheter
  • Active neuromuscular blockade at initiation of the transition trial
  • Significant hemodynamic instability
  • Any clinical condition for which reduction of sedation or transition to assisted ventilation is considered unsafe by the treating physician

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: COHORT
  • Time Perspectives: PROSPECTIVE

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Experimental: Protocolized Transition to Assisted Mechanical Ventilation

Participants receiving controlled mechanical ventilation will undergo gradual reduction of sedation to permit spontaneous respiratory activity, followed by a 30-minute transition to assisted mechanical ventilation. PEEP will remain at the pre-transition value and FiO₂ will remain unchanged whenever clinically feasible. Inspiratory assistance will be titrated to maintain tidal volume at approximately 6-8 mL/kg predicted body weight. Physiological measurements will be recorded continuously, and the procedure will be terminated if prespecified intolerance or safety criteria occur.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure respiratory rate (breaths per minute).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the lung elastance, the chest wall elastance and the total respiratory system elastance (all measured in cmH₂O/L).

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. The measured variables will include the transpulmonary pressure, which is measured in cmH₂O. During the baseline measurement both statics and dynamics measurements will be calculated, whereas during the assisted phase the investigator will include only the dynamic measurements.

During the first thirty minutes of assisted ventilation.
Difference in Respiratory Mechanics between succesfull and failed transition using a pneumotachograph
Time Frame: During the first thirty minutes of assisted ventilation.

The investigator will measure the respiratory mechanics at baseline, after the first five minutes of assisted ventilation and at 30 minutes of assisted ventilation. We will measure tidal volume (mLs).

During the first thirty minutes of assisted ventilation.

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first thirty minutes of assisted ventilation.

The investigator will measure the variation in the global inhomogeneity index derived by using electrical impedance tomography.

During the first thirty minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.

The investigator will measure the end-expiratory lung impedance, EELI, which is measured in ohms.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.

The investigator will measure the ventral to dorsal ratio using the electrical impedance tomography.

During the first 30-minutes of assisted ventilation.
Differences in electrical impedance tomography variables between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.

The investigator will measure the variation in the pendelluft phenomenon using the impedance amplitude values.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation
Time Frame: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in esophageal pressure swings, ΔPes in cmH₂O, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.
Differences in respiratory effort between successful and failed transition to assisted ventilation.
Time Frame: During the first 30-minutes of assisted ventilation.

The investigator will measure the differences in the esophageal pressure-time product measured in cmH₂O⋅s/min, between the beginning of the transition phase and at the final 5 minutes of the 30-minute trial.

During the first 30-minutes of assisted ventilation.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Apostolos - Alkiviadis Menis, MD, PhD, General University Hospital of Larisa, University of Thessaly
  • Study Director: Makris, MD, PhD, General University Hospital of Larisa, University of Thessaly

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 1, 2026

Primary Completion (Estimated)

October 1, 2028

Study Completion (Estimated)

December 1, 2028

Study Registration Dates

First Submitted

September 8, 2026

First Submitted That Met QC Criteria

October 23, 2026

First Posted (Actual)

October 30, 2026

Study Record Updates

Last Update Posted (Actual)

November 16, 2026

Last Update Submitted That Met QC Criteria

November 13, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe